Please use this identifier to cite or link to this item:
Title: Outcomes studied in leukaemia clinical trials : a need for harmonisation?
Authors: Said, Dylan
Borg, John Joseph
Attard Pizzuto, Maresca
Serracino-Inglott, Anthony
Keywords: Leukemia -- Treatment
Leukemia -- Diagnosis
Clinical trials -- Decision making
Clinical trials -- Evaluation
Technology assessment, Biomedical
Communication in medicine -- Evaluation
Issue Date: 2019-09
Publisher: University of Malta. Department of Pharmacy
Citation: Said, D., Borg, J. J., Attard Pizzuto, M., & Serracino-Inglott, A. (2019, September). Outcomes studied in leukaemia clinical trials: a need for harmonisation?. Poster session presented at the FIP World Congress of Pharmacy and Pharmaceutical Sciences, Abu Dhabi, United Arab Emirates.
Abstract: A poster presentation regarding outcomes studied in leukaemia clinical trials. Introduction: Heterogeneity in outcomes measured in clinical trials (CTs) and clinical studies for antineoplastic therapies presents as a major barrier to evidence synthesis, increasing the complexity of regulatory, policy and healthcare decision-making. Highlighting the magnitude of inconsistency, sources report that over 25,000 of outcomes in cancer trials have only been used once or twice. Aims: •To identify unique efficacy parameters investigated in leukaemia CTs; •To determine the degree of variability of efficacy outcomes studied in trials for the following four main leukaemia subtypes: Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL) and Chronic Myeloid Leukaemia (CML).
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Outcomes_studied_in_leukaemia_clinical_trials_a_need_for_harmonisation_2019.pdf1.68 MBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.